INTRAVENOUS DMT ADMINISTRATION METHOD FOR DMT-ASSISTED PSYCHOTHERAPY
A method of inducing a psychedelic state in an individual by administering DMT, a salt of DMT, analogs thereof, or derivatives thereof to an individual with a continuous perfusion system and inducing a psychedelic state. A method of inducing a psychedelic state in an individual safely, by administering DMT, a salt of DMT, analogs thereof, or derivatives thereof to an individual with a continuous perfusion system, inducing a psychedelic state, and adjusting or ending the psychedelic state on demand. A method of providing a short lasting psychedelic treatment of minutes to 1-2 hours, by administering DMT, a salt of DMT, analogs thereof, or derivatives thereof to an individual with a continuous perfusion system and providing psychedelic treatment for minutes to 1-2 hours. A method of determining a dose of DMT for an individual.
1 . A method of inducing a psychedelic state in an individual, including the steps of:
administering a composition chosen from the group consisting of DMT, a salt of DMT, analogs thereof, and derivatives thereof to an individual with a continuous perfusion system; and
inducing a psychedelic state.
2 . The method of claim 1 , wherein the composition is administered continuously in a dose of 0.1-5 mg/minute.
3 . The method of claim 2 , wherein the composition is administered continuously for 5 minutes to 5 hours.
4 . The method of claim 3 , wherein said inducing step is further defined as inducing a stable and controlled psychedelic state lasting minutes to hours.
5 . The method of claim 1 , wherein said administering step is further defined as administering the composition to an individual with anxiety or an individual who is using the composition for a first time.
6 . The method of claim 1 , further including the step of inducing positive acute subjective effects chosen from the group consisting of “good drug effect”, “drug liking”, “well-being”, “oceanic boundlessness”, “experience of unity”, “spiritual experience”, “blissful state”, “insightfulness”, “mystical-type experience”, positively experienced “psychedelic effects”, “aspects of ego-dissolution” if experienced without anxiety, and combinations thereof.
7 . The method of claim 1 , further including before said administering step, the step of administering a bolus dose of a composition chosen from the group consisting of DMT, a salt of DMT, analogs thereof, and derivatives thereof to the individual.
8 . The method of claim 7 , wherein the bolus dose of the composition is 1-100 mg.
9 . The method of claim 7 , wherein the bolus dose is administered over 30-60 seconds.
10 . The method of claim 7 , wherein the individual has used the composition before or requires a strong peak experience.
11 . The method of claim 1 , wherein said inducing step is performed rapidly within seconds to minutes.
12 . The method of claim 1 , wherein said inducing step results in a stable psychedelic state after 45 minutes.
13 . The method of claim 1 , further including the step of stopping the psychedelic state rapidly within 10-30 minutes.
14 . The method of claim 1 , further including the step of obtaining rapid/instant verbal feedback from the individual on the intensity of a psychedelic experience.
15 . The method of claim 14 , further including the step of rapidly adjusting the psychedelic state based on the verbal feedback or other feedback and providing a lower or higher intensity experience within minutes.
16 . The method of claim 1 , wherein the individual is resting in a controlled quiet environment protected from loud noise and in the presence of a therapist.
17 . The method of claim 1 , further including the steps of measuring the psychedelic state of the individual at the end of the treatment session and adjusting a dose based on the measurements in a subsequent treatment session.
18 . The method of claim 17 , wherein said measuring step is further defined as a measure chosen from the group consisting of the Adjective Mood Rating Scale (AMRS), the 5-Dimensional Altered States of Consciousness (5D-ASC), the States of Consciousness Questionnaire (SCQ), and the Spiritual Realm Questionnaire (SRQ).
19 . The method of claim 1 , further including the step of measuring plasma levels of the composition, and adjusting the dose of the composition in a future treatment session based on the measurement.
20 . A method of inducing a psychedelic state in an individual safely, including the steps of:
administering a composition chosen from the group consisting of DMT, a salt of DMT, analogs thereof, and derivatives thereof to an individual with a continuous perfusion system;
inducing a psychedelic state; and
adjusting or ending the psychedelic state on demand.
21 . The method of claim 20 , wherein said inducing step and said adjusting or ending step can be controlled based on the duration of the continuous perfusion system to last from minutes to a few hours.
22 . The method of claim 20 , wherein the composition is administered in a dose of 0.1-5 mg/minute for 5 minutes to 5 hours.
23 . The method of claim 20 , further including before said administering step, the step of administering a bolus dose of 1-100 mg of a composition chosen from the group consisting of DMT, a salt of DMT, analogs thereof, and derivatives thereof to the individual.
24 . A method of providing a short lasting psychedelic treatment of minutes to 1-2 hours, including the steps of:
administering a composition chosen from the group consisting of DMT, a salt of DMT, analogs thereof, and derivatives thereof to an individual with a continuous perfusion system; and
providing psychedelic treatment for minutes to 1-2 hours.
25 . The method of claim 24 , wherein the composition is administered in a dose of 0.1-5 mg/minute for 5 minutes to 5 hours.
26 . The method of claim 24 , further including before said administering step, the step of administering a bolus dose of 1-100 mg of a composition chosen from the group consisting of DMT, a salt of DMT, analogs thereof, and derivatives thereof to the individual.
27 . A method of determining a dose of DMT for an individual, including the steps of:
administering different rates of perfusion of a composition chosen from the group consisting of DMT, a salt of DMT, analogs thereof, and derivatives thereof to an individual; and
adjusting the dose to provide more positive acute effects than negative acute effects in the individual.
28 . The method of claim 27 , wherein the positive acute effects are chosen from the group consisting of “good drug effect”, “drug liking”, “well-being”, “oceanic boundlessness”, “experience of unity”, “spiritual experience”, “blissful state”, “insightfulness”, “mystical-type experience”, positively experienced “psychedelic effects”, “aspects of ego-dissolution” if experienced without anxiety, and combinations thereof, and wherein the negative acute effects are chosen from the group consisting of “bad drug effect”, “anxiety”, “fear”, increased ratings of “anxious ego-dissolution”, descriptions of acute paranoia, states of panic, and combinations thereof.
29 . A method of therapy, including the steps of:
administering an intermediate “good effect dose” of a composition chosen from the group consisting of DMT, a salt of DMT, analogs thereof, and derivatives thereof to an individual; and
inducing positive acute drug effects that are known to be associated with more positive long-term responses in psychiatric patients.
30 . The method of claim 29 , wherein the positive acute effects are chosen from the group consisting of “good drug effect”, “drug liking”, “well-being”, “oceanic boundlessness”, “experience of unity”, “spiritual experience”, “blissful state”, “insightfulness”, “mystical-type experience”, positively experienced “psychedelic effects”, “aspects of ego-dissolution” if experienced without anxiety, and combinations thereof.
31 . The method of claim 29 , further including the step of treating a medical condition chosen from the group consisting of depression, anxiety, substance use disorder, other addiction, personality disorder, eating disorder, post-traumatic stress disorder, obsessive compulsive disorder, various pain disorders, migraine, cluster headache, and palliative care.
32 . A method of therapy, including the steps of:
administering an “ego-dissolution” dose of a composition chosen from the group consisting of DMT, a salt of DMT, analogs thereof, and derivatives thereof to an individual; and
providing ego-dissolution.
33 . The method of claim 32 , wherein the individual has a condition chosen from the group consisting of severe pain disorders, cancer, in palliative care, personality disorder, and combinations thereof.
34 . A method of adjusting a psychedelic state in an individual in real time while effects of DMT have already started in the individual, including the steps of:
adjusting a psychedelic state in an individual in real time while effects of DMT, a salt of DMT, analogs thereof, and derivatives thereof have already started in the individual, by adjusting a rate of the DMT perfusion to increase or decrease the intensity and/or duration of the psychedelic state based on the individual's feedback or a therapist's assessment of the individual's state.
35 . The method of claim 34 , further including, before said adjusting step, the step of starting a perfusion with 1 mg of DMT/minute over 10-30 minutes in the individual, and wherein said adjusting step is further defined as the individual deciding whether to increase or decrease the dose to 1.2 mg or 0.8 mg/minute DMT, respectively, and the individual repeating said deciding step again every 10-30 minutes to further optimize the dose to the individual's need.
36 . The method of claim 35 , wherein said deciding step based on subjective effect strength (any drug effect) and positive versus negative drug effects.